Collider constraints on electroweakinos in the presence of a light gravitino

Using the GAMBIT global fitting framework, we constrain the MSSM with an eV-scale gravitino as the lightest supersymmetric particle, and the six electroweakinos (neutralinos and charginos) as the only other light new states. We combine 15 ATLAS and 12 CMS searches at 13 TeV, along with a large collection of ATLAS and CMS measurements of Standard Model signatures. This model, which we refer to as the G~-EWMSSM, exhibits quite varied collider phenomenology due to its many permitted electroweakino production processes and decay modes. Characteristic G~-EWMSSM signal events have two or more Standard Model bosons and missing energy due to the escaping gravitinos. While much of the G~-EWMSSM parameter space is excluded, we find several viable parameter regions that predict phenomenologically rich scenarios with multiple neutralinos and charginos within the kinematic reach of the LHC during Run 3, or the High Luminosity LHC. In particular, we identify scenarios with Higgsino-dominated electroweakinos as light as 140 GeV that are consistent with our combined set of collider searches and measurements. The full set of G~-EWMSSM parameter samples and GAMBIT input files generated for this work is available via Zenodo

Urban transformation with TURAS open innovations; opportunities for transitioning through transdisciplinarity

Transitioning is a unidirectional process of mainstreaming sustainability within normative societal behaviour, which communities hope will build resilience, reduce our dependence on distant resources and lead to the transformation towards more sustainable living as an end product. Throughout Europe there are numerous examples and pilot or demonstration projects that illustrate tools, practices, mechanisms, pathways and policies for how transitioning can be guided and a transformation can be achieved. This paper draws on the experience of the TURAS project by illustrating some of the diverse open innovation opportunities that have been derived using novel transdisciplinary approaches. The paper concludes with identifying possible ways forward by utilising the TURAS innovations to enable the transformation of urban communities

Collider constraints on electroweakinos in the presence of a light gravitino

Using the GAMBIT global fitting framework, we constrain the MSSM with an eV-scale gravitino as the lightest supersymmetric particle, and the six electroweakinos (neutralinos and charginos) as the only other light new states. We combine 15 ATLAS and 12 CMS searches at 13 TeV, along with a large collection of ATLAS and CMS measurements of Standard Model signatures. This model, which we refer to as the G~-EWMSSM, exhibits quite varied collider phenomenology due to its many permitted electroweakino production processes and decay modes. Characteristic G~-EWMSSM signal events have two or more Standard Model bosons and missing energy due to the escaping gravitinos. While much of the G~-EWMSSM parameter space is excluded, we find several viable parameter regions that predict phenomenologically rich scenarios with multiple neutralinos and charginos within the kinematic reach of the LHC during Run 3, or the High Luminosity LHC. In particular, we identify scenarios with Higgsino-dominated electroweakinos as light as 140 GeV that are consistent with our combined set of collider searches and measurements. The full set of G~-EWMSSM parameter samples and GAMBIT input files generated for this work is available via Zenodo

Exploring gastrointestinal variables affecting drug and formulation behavior: methodologies, challenges and opportunities

Various gastrointestinal (GI) factors affect drug and formulation behavior after oral administration, including GI transfer, motility, pH and GI fluid volume and composition. An in-depth understanding of these physiological and anatomical variables is critical for a continued progress in oral drug development. In this review, different methodologies (invasive versus non-invasive) to explore the impact of physiological variables on formulation behavior in the human GI tract are presented, revealing their strengths and limitations. The techniques mentioned allow for an improved understanding of the role of following GI variables: gastric emptying (magnetic resonance imaging (MRI), scintigraphy, acetaminophen absorption technique, ultrasonography, breath test, intraluminal sampling and telemetry), motility (MRI, small intestinal/colonic manometry and telemetry), GI volume changes (MRI and ultrasonography), temperature (telemetry) and intraluminal pH (intraluminal sampling and telemetry)

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

OBJECTIVE: To evaluate whether eculizumab helps patients with anti-acetylcholine receptor-positive (AChR+) refractory generalized myasthenia gravis (gMG) achieve the Myasthenia Gravis Foundation of America (MGFA) post-intervention status of minimal manifestations (MM), we assessed patients' status throughout REGAIN (Safety and Efficacy of Eculizumab in AChR+ Refractory Generalized Myasthenia Gravis) and its open-label extension. METHODS: Patients who completed the REGAIN randomized controlled trial and continued into the open-label extension were included in this tertiary endpoint analysis. Patients were assessed for the MGFA post-intervention status of improved, unchanged, worse, MM, and pharmacologic remission at defined time points during REGAIN and through week 130 of the open-label study. RESULTS: A total of 117 patients completed REGAIN and continued into the open-label study (eculizumab/eculizumab: 56; placebo/eculizumab: 61). At week 26 of REGAIN, more eculizumab-treated patients than placebo-treated patients achieved a status of improved (60.7% vs 41.7%) or MM (25.0% vs 13.3%; common OR: 2.3; 95% CI: 1.1-4.5). After 130 weeks of eculizumab treatment, 88.0% of patients achieved improved status and 57.3% of patients achieved MM status. The safety profile of eculizumab was consistent with its known profile and no new safety signals were detected. CONCLUSION: Eculizumab led to rapid and sustained achievement of MM in patients with AChR+ refractory gMG. These findings support the use of eculizumab in this previously difficult-to-treat patient population. CLINICALTRIALSGOV IDENTIFIER: REGAIN, NCT01997229; REGAIN open-label extension, NCT02301624. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that, after 26 weeks of eculizumab treatment, 25.0% of adults with AChR+ refractory gMG achieved MM, compared with 13.3% who received placebo

Minimal Symptom Expression' in Patients With Acetylcholine Receptor Antibody-Positive Refractory Generalized Myasthenia Gravis Treated With Eculizumab

The efficacy and tolerability of eculizumab were assessed in REGAIN, a 26-week, phase 3, randomized, double-blind, placebo-controlled study in anti-acetylcholine receptor antibody-positive (AChR+) refractory generalized myasthenia gravis (gMG), and its open-label extension

Composition of gastric fluids under fasting and fed conditions

status: accepte

In vivo characterization of supersaturation

status: accepte

Investigating the link between gastric motility and distribution of an orally administered drug in the stomach of fasted healthy volunteers

status: publishe